Lewanczuk R Z, Benishin C G, Shan J, Pang P K
Department of Physiology, University of Alberta, Edmonton, Canada.
J Cardiovasc Pharmacol. 1994;23 Suppl 2:S23-6.
To determine the clinical significance of parathyroid hypertensive factor (PHF), physiological studies previously performed in animal models of hypertension were parallelled by human studies. These studies revealed that PHF-like activity is present in human hypertension, where it correlates with the salt-sensitive, low-renin state. As in spontaneously hypertensive rats, both supplemental calcium and calcium-channel blockers appear to be useful in the treatment of PHF-related hypertension. In primary hyperparathyroid patients, PHF presence is linked with the presence of hypertension. Postparathyroidectomy blood pressure falls in parallel with PHF levels. These preliminary human studies suggest that PHF may be a useful marker in the treatment of hypertension.
为了确定甲状旁腺高血压因子（PHF）的临床意义，先前在高血压动物模型中进行的生理学研究与人体研究同时开展。这些研究表明，人类高血压中存在类似PHF的活性，且与盐敏感性、低肾素状态相关。与自发性高血压大鼠一样，补充钙剂和钙通道阻滞剂似乎都对治疗与PHF相关的高血压有效。在原发性甲状旁腺功能亢进患者中，PHF的存在与高血压的存在有关。甲状旁腺切除术后血压随PHF水平下降。这些初步的人体研究表明，PHF可能是高血压治疗中的一个有用标志物。
